Literature DB >> 19145162

Aberrant angiogenic characteristics of human brain arteriovenous malformation endothelial cells.

Mark N Jabbour1, James B Elder, Christian G Samuelson, Shabnam Khashabi, Florence M Hofman, Steven L Giannotta, Charles Y Liu.   

Abstract

OBJECTIVE: To identify and characterize the phenotypic and functional differences of endothelial cells derived from cerebral arteriovenous malformations (AVM), as compared with endothelial cells derived from a normal brain.
METHODS: Isolated AVM brain endothelial cells and control brain endothelial cells were evaluated immunohistochemically for expression of the endothelial cell markers von Willebrand factor and CD31, as well as angiogenic factors including vascular endothelial growth factor A, interleukin-8, and endothelin-1. Vascular endothelial growth factor receptors 1 and 2 were also evaluated using immunohistochemistry techniques. Functional assays evaluated cell proliferation, cytokine production, tubule formation, and cell migration using the modified Boyden chamber technique.
RESULTS: Endothelial cells derived from AVMs expressed high levels of vascular endothelial growth factor A and significantly overexpressed the vascular endothelial growth factor receptors 1 and 2 (P < 0.05), as compared with control endothelial cells. In addition, comparison to control brain endothelial cells demonstrated that AVM brain endothelial cells proliferated faster, migrated more quickly, and produced aberrant tubule-like structures.
CONCLUSION: Endothelial cells derived from cerebral AVMs are highly activated cells overexpressing proangiogenic growth factors and exhibiting abnormal functions consistent with highly activated endothelial cells.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19145162     DOI: 10.1227/01.NEU.0000334417.56742.24

Source DB:  PubMed          Journal:  Neurosurgery        ISSN: 0148-396X            Impact factor:   4.654


  25 in total

1.  Elevated endothelial Sox2 causes lumen disruption and cerebral arteriovenous malformations.

Authors:  Jiayi Yao; Xiuju Wu; Daoqin Zhang; Lumin Wang; Li Zhang; Eric X Reynolds; Carlos Hernandez; Kristina I Boström; Yucheng Yao
Journal:  J Clin Invest       Date:  2019-06-24       Impact factor: 14.808

2.  Experimental study of temperature-sensitive chitosan/β-glycerophosphate embolic material in embolizing the basicranial rete mirabile in swines.

Authors:  Xianbin Ning; Changfu Zhao; Jinfeng Pang; Zhaoyi Ding; Yubo Wang; Kan Xu; Hao Chen; Bingwei Li; Q I Luo
Journal:  Exp Ther Med       Date:  2015-05-07       Impact factor: 2.447

Review 3.  Pulmonary arteriovenous malformations after the superior cavopulmonary shunt: mechanisms and clinical implications.

Authors:  Minoo N Kavarana; Jeffrey A Jones; Robert E Stroud; Scott M Bradley; John S Ikonomidis; Rupak Mukherjee
Journal:  Expert Rev Cardiovasc Ther       Date:  2014-04-23

Review 4.  Pathogenesis of non-hereditary brain arteriovenous malformation and therapeutic implications.

Authors:  Takahiro Ota; Masaki Komiyama
Journal:  Interv Neuroradiol       Date:  2020-02-05       Impact factor: 1.610

Review 5.  Biology of cerebral arteriovenous malformations with a focus on inflammation.

Authors:  Nikolaos Mouchtouris; Pascal M Jabbour; Robert M Starke; David M Hasan; Mario Zanaty; Thana Theofanis; Dale Ding; Stavropoula I Tjoumakaris; Aaron S Dumont; George M Ghobrial; David Kung; Robert H Rosenwasser; Nohra Chalouhi
Journal:  J Cereb Blood Flow Metab       Date:  2014-11-19       Impact factor: 6.200

6.  Gene expression profiling of blood in brain arteriovenous malformation patients.

Authors:  Shantel M Weinsheimer; Huichun Xu; Achal S Achrol; Boryana Stamova; Charles E McCulloch; Ludmila Pawlikowska; Yingfang Tian; Nerissa U Ko; Michael T Lawton; Gary K Steinberg; Steven D Chang; Glen Jickling; Bradley P Ander; Helen Kim; Frank R Sharp; William L Young
Journal:  Transl Stroke Res       Date:  2011-12-01       Impact factor: 6.829

7.  Endothelial signaling and the molecular basis of arteriovenous malformation.

Authors:  Deepak Atri; Bruno Larrivée; Anne Eichmann; Michael Simons
Journal:  Cell Mol Life Sci       Date:  2013-09-28       Impact factor: 9.261

8.  Pulmonary artery endothelial cell phenotypic alterations in a large animal model of pulmonary arteriovenous malformations after the Glenn shunt.

Authors:  Minoo N Kavarana; Rupak Mukherjee; Shaina R Eckhouse; William F Rawls; Christina Logdon; Robert E Stroud; Risha K Patel; Elizabeth K Nadeau; Francis G Spinale; Eric M Graham; Geoffrey A Forbus; Scott M Bradley; John S Ikonomidis; Jeffrey A Jones
Journal:  Ann Thorac Surg       Date:  2013-08-20       Impact factor: 4.330

9.  Bevacizumab attenuates VEGF-induced angiogenesis and vascular malformations in the adult mouse brain.

Authors:  Espen J Walker; Hua Su; Fanxia Shen; Vincent Degos; Gregory Amend; Kristine Jun; William L Young
Journal:  Stroke       Date:  2012-05-08       Impact factor: 7.914

10.  Proof-of-concept single-arm trial of bevacizumab therapy for brain arteriovenous malformation.

Authors:  Rachel Muster; Nerissa Ko; Wade Smith; Hua Su; Melissa A Dickey; Jeffrey Nelson; Charles E McCulloch; Patricia K Sneed; Jennifer L Clarke; David A Saloner; Laura Eisenmenger; Helen Kim; Daniel L Cooke
Journal:  BMJ Neurol Open       Date:  2021-03-17
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.